TABLE I.
Patient characteristics by EGFR mutation status
| Characteristic | Overall | EGFR WT | EGFR-positive | p Value |
|---|---|---|---|---|
| Patients (n) | 543 | 422 | 121 | |
| Age at diagnosis (years) | ||||
| Median | 66 | 67 | 66 | 0.75a |
| IQR | 58–74 | 58–73 | 55–77 | |
| ECOG PS [n (%)] | ||||
| 0 | 23 (4) | 14 (3) | 9 (7) | 0.008b |
| 1 | 229 (42) | 166 (39) | 63 (52) | |
| 2 | 160 (29) | 129 (31) | 31 (26) | |
| 3 | 116 (21) | 100 (24) | 16 (13) | |
| 4 | 15 (3) | 13 (3) | 2 (2) | |
| Asian ethnicity [n (%)] | ||||
| Yes | 123 (23) | 64 (15) | 59 (49) | <0.001b |
| No | 420 (77) | 358 (85) | 62 (51) | |
| Sex | ||||
| Women | 327 (60) | 247 (59) | 80 (66) | 0.14b |
| Men | 216 (40) | 175 (41) | 41 (34) | |
| Smoking (pack–years) | ||||
| Median | 21 | 30 | 0 | <0.001a |
| IQR | 0–40 | 10–40 | 0–5 | |
| Chemotherapy | ||||
| Yes | 267 (49) | 208 (49) | 59 (49) | 1b |
| No | 276 (51) | 214 (51) | 62 (51) | |
| EGFR TKI | ||||
| Yes | 222 (41) | 117 (28) | 105 (87) | <0.001b |
| No | 321 (59) | 305 (72) | 16 (13) |
a
Calculated using the Kruskal–Wallis rank-sum test.
b
Calculated using the Fisher exact test.
WT = wild type; IQR = interquartile range; ECOG PS = Eastern Cooperative Oncology Group performance status; EGFR TKI = epidermal growth factor receptor tyrosine kinase inhibitor.